Juzina

Sitagliptin Hydrochloride Monohydrate, the active ingredient in Juzina, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve blood glucose control when used with diet and exercise, in combination with other antidiabetic agents as needed.

GNH USA supplies Juzina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import.

Sitagliptin is a DPP‑4 inhibitor used to improve glycemic control in type 2 diabetes. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial blood glucose when added to diet and exercise. - Type 2 diabetes mellitus (combined with metformin): provides additional glucose reduction in patients inadequately controlled on metformin alone. - Type 2 diabetes mellitus (combined with insulin or sulfonylureas): enhances overall glycemic control while allowing lower doses of insulin or sulfonylureas.

Sitagliptin may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain. - Upper respiratory tract infection: symptoms such as cough and congestion. - Nausea: feeling of stomach upset. - Diarrhoea: loose stools. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain possibly indicating pancreatic inflammation. - Severe allergic reactions: rash, swelling, or difficulty breathing. - Joint pain: unexplained arthralgia. - Elevated liver enzymes: signs of hepatic stress. - Bullous pemphigoid: rare skin blistering disorder. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Before prescribing Juzina, clinicians should consider several precautionary measures. - Renal impairment: assess kidney function and adjust dose or avoid in severe cases. - Hepatic impairment: use with caution in patients with liver disease. - History of pancreatitis: avoid use due to risk of recurrence. - Concomitant insulin or sulfonylureas: monitor for hypoglycaemia and adjust doses. - Pregnancy and breastfeeding: safety not established; prescribe only if benefits outweigh risks. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Sitagliptin can interact with other medicines, requiring attention to the interaction level.

Major Interactions (Avoid): - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may increase sitagliptin exposure and risk of adverse effects. - Combined use with insulin or sulfonylureas: can cause severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce sitagliptin plasma concentrations, decreasing efficacy. - Diuretics (e.g., thiazides): may affect glucose control, requiring monitoring. - Warfarin: potential alteration of INR, necessitating regular coagulation checks.